IP Library Granted Patent US 9,637,548
Granted Patent B2
US 9,637,548 · App. 13/201,726 · Granted May 2, 2017

Methods and compositions for diagnosis and treatment of cancer

Inventors: Ugur Sahin (Mainz, DE); Özlem Türeci (Mainz, DE); Michael Koslowski (Frankfurt, DE)
Assignees: GANYMED PHARMACEUTICALS AG; JOHANNES GUTENBERG-UNIVERSITAT MAINZ
C07K16/3046G01N33/57419G01N33/57446A61K2039/505C07K2317/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,637,548
App. No.
13/201,726
Granted
May 2, 2017
Kind
B2
Abstract

The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of colorectal, in particular colonic, and gastric tumor tissues and colorectal, in particular colonic, and gastric tissues, and which represent targets for therapy or diagnosis of such tumor diseases in a subject.

Claims (8)

1. A method of detecting a tumor antigen peptide comprising the amino acid sequence of a tumor antigen encoded by a nucleic acid sequence of SEQ ID NO:1 in a patient, the method comprising

obtaining a biological sample isolated from said patient,

contacting said biological sample with an antibody which binds to amino acids 120-132 of SEQ ID NO:2 to form a detectable complex, and

detecting whether said tumor antigen peptide is present in said sample by detecting the formation of said complex.

2. The method of claim 1 , wherein the biological sample is from a tissue or organ wherein the cells when the tissue or organ is free of tumors do not detectably express said tumor antigen and/or a nucleic acid encoding said tumor antigen.

3. The method of claim 1 , wherein the antibody further comprises a detectable label.

4. The method of claim 1 , wherein the tumor antigen comprises the amino acid sequence according to SEQ ID NO: 2.

5. The method of claim 1 , wherein the antibody is a monoclonal, chimeric, human or humanized antibody, or is a fragment of an antibody or a synthetic antibody.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2020
From: JOHANNES GUTENBERG-UNIVERSITAT MAINZ
To: TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
Reel/Frame 052226/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2020
From: GANYMED PHARMACEUTICALS GMBH
To: BIONTECH SE
Reel/Frame 052124/0212 →
CHANGE OF NAME Recorded Mar 5, 2020
From: GANYMED PHARMACEUTICALS AG
To: GANYMED PHARMACEUTICALS GMBH
Reel/Frame 052110/0759 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2011
From: SAHIN, UGUR; TURECI, OZLEM; KOSLOWSKI, MICHAEL
To: GANYMED PHARMACEUTICALS AG; JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Reel/Frame 026836/0904 →
Priority Claims (1)
EP 09002458 · Feb 20, 2009 · regional
Continuity (2)
Provisional Application 61154159 · Feb 20, 2009
Related Publication 20110318264A1 · Dec 29, 2011